CHARACTERIZATION OF C-TERMINAL TRUNCATIONS OF MOLONEY MULV PR65GAG (MEETING ABSTRACT)

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

CHARACTERIZATION OF C-TERMINAL TRUNCATIONS OF MOLONEY MULV PR65GAG (MEETING ABSTRACT)

Fifteenth Symposium of the International Association for Comparative Research on Leukemia and Related Diseases. October 6-11, 1991, Padova/Venice, Italy, p. 20, 1991.. Unique Identifier : AIDSLINE ICDB/92682376
Ernst S; Gorelick R; Rein A; Lab. of Molecular Virology and Carcinogenesis, ABL-Basic Res.; Program, Frederick, MD 21702

Abstract: In an attempt to define functional domains of the gag precursor in Moloney MuLV, we have generated a number of mutants in the gag gene of an infectious molecular clone of this virus. We introduced a series of termination codons at different points in the p30ca and p10nc coding regions. Mammalian cells were transfected with each of these mutants, and stable transfectants were isolated. Surprisingly, these cells all released the viral proteins into the culture fluid in pelletable form. We are now characterizing the structures containing these viral proteins. One of these mutants lacks only 17 amino acids from the C-terminus of p10nc (plus all of pol). Northern analysis shows that the particles encoded by this mutant package viral RNA normally, and also that the denatured viral RNA in these particles is the same size as wild-type RNA, as expected. However, when the particles are lysed and the RNA analyzed by velocity sedimentation under nondenaturing conditions, we find that the RNA complex isolated from these particles deposits somewhat more slowly than that from wild-type particles. The results suggest that the dimeric RNA present in retroviral particles can exist in different conformational states, and also that viral proteins can influence the conformation of the RNA dimer.

Keywords: Animal Gene Products, gag/*ANALYSIS Leukemia, Experimental/*GENETICS Moloney Leukemia Virus/*GENETICS Protein Conformation Protein Denaturation RNA, Viral/*ANALYSIS Transfection ABSTRACT
920830
M9281109

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .